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ess: saltini@med.uniromSummary Since after the first streptomycin 1944 trials, anti-tuberculous che-
motherapy research has been focused upon establishing drug combination regimens
capable of overcoming drug resistance and amenable to ambulatory treatment in
resource strapped countries. The first milestone being the 1959 Madras trial
comparing home and sanatorium treatment in South India. Subsequently, the MRC
trials led Fox and Mitchison to indicate rifampicin, isoniazid and pyrazinamide as the
first line drugs for short course, 6 month, regimens and the 1982 Hong Kong Chest
Service trials established intermittent therapy as the ambulatory treatment standard
for directly observed therapy (DOT). The rising of the HIV epidemic at the beginning of
the 1980s has refuelled tuberculosis spread in Africa and Asia and contributed to the
expansion of drug-resistant tuberculosis worldwide making the development of new
drugs and drug regimens for ambulatory treatment a top priority.
Led by biotechnological advances, molecular biology has been brought into TB
laboratory diagnosis for the highly sensitive and specific rapid identification of
Mycobacterium tuberculosis in biological samples. The field of immunological
diagnosis of TB infection, dominated since the early 1900s by the intradermal
tuberculin reaction has been put back in motion by the discovery of M. tuberculosis-
specific proteins and peptides, now employed in blood tests of high sensitivity and
specificity for the diagnosis of latent TB which may help with the identification of
contacts at higher risk of active disease and the eradication of pidemic cases.
& 2006 Elsevier Ltd. All rights reserved.Chemotherapy
Soon after streptomycin discovery and its clinical
application to tuberculosis treatment it became
apparent that the bacillus was capable of rapidly
developing drug resistance. It was then found thatElsevier Ltd. All rights reserv
a2.it.para-aminosalicylic acid (PAS) could be used in
combination with streptomycin to prevent, or
delay, streptomycin resistance.1–3 With the discov-
ery of the anti-tuberculous bactericidal activity of
isoniazid, it was found that it was much more
powerful in combinations with streptomycin and
PAS than when used alone and the first combination
chemotherapy regimens were standardized. These
included daily isoniazid, streptomycin and highed.
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streptomycin, isoniazid and PAS resistance and
their entire course was extended to 18–24 months,
using pneumothorax in the more advanced cases.4–6The 1950s and the 1960s: from the
sanatorium to home treatment
The introduction of highly effective chemotherapy
regimens allowed the design of ambulatory inter-
ventions for active, AFB sputum positive, cavitary
tuberculosis in order to reduce the need for
sanatorium isolation, to make tuberculosis therapy
less costly for health programs and more socially
acceptable to patients and their families. A 12
month randomized controlled trial of isoniazid plus
PAS in the same cachet (200mg and 10 g, respec-
tively for the average above 45 kg person) was
launched at the Tuberculosis Chemotherapy Centre
of Madras (India), where 193 active tuberculosis
patients were enrolled of whom 96 were treated at
home and 97 in sanatorium. Several aspects of this
substantial Madras report are of great interest.7
Firstly, with about 4% isoniazid resistant and 3% PAS
resistant subjects at the start of the trial, sputum
positive frequencies at 12 months were similar in
the two arms with about 90% bacteriological cure
rates. Secondly, the stark reduction in the number
of family crisis caused by sanatorium isolation,
spouse infidelity among them, was a likely factor in
bettering compliance in the home arm of the study,
as more than 10% abandoned the sanatorium while
less than 1% defaulted home treatment. Finally,
this study established the role of chemotherapy,
diet and bed rest by showing that in spite of
returning to part or full-time work and having no
bed rest, 90% of home-treated patients had the
same bacteriologic result of bed bound, well-fed
sanatorium guests. In addition, the study showed
that domiciliary treatment did not increase the risk
of infection among family members. This way, the
Madras results showed that with a highly organized
domiciliary service concentrating upon persuading
patients to attend, especially when there were
signs that they were becoming inattentive to
treatment, it was possible to design large, cost
effective tuberculosis programs.
As a large USA study showed that 15% of patients
under treatment with isoniazid, streptomycin and
PAS in various combination abandoned treatment
because of toxicity, with PAS been responsible of
twice as much side effects as streptomycin and
isoniazid,8 the next step toward an effective
outpatient treatment was then to shorten itsduration and to reduce the number and intensity
of side effects.
In this regard, a British Medical Research Council
trial evaluated four regimens comprised of an
initial 3 month in-hospital treatment followed 9
months of ambulatory chemotherapy consisting of
(i) daily streptomycin, isoniazid and PAS (SHP)
followed by daily isoniazid plus PAS (HP), (ii) daily
streptomycin, isoniazid and ethambutol (SHE)
followed by daily isoniazid plus ethambutol (HE),
(iii) daily streptomycin, isoniazid and rifampicin
(SHR) followed by daily isoniazid plus rifampicin
(HR) and (iv) streptomycin, isoniazid and PAS (SHP)
followed by twice weekly streptomycin plus high
dose isoniazid (SH2).
9 While all regimens were
highly effective with less than 1–3% bacteriological
failures, vestibular toxicity and gastric upsets,
attributed to streptomycin PAS, were the side
effects more often reported. Ethambutol and
rifampicin regimens had the least burden of
toxicity and, conversely, the highest compliance
rates.
On the other hand, the cost of treatments was a
serious concern in developing countries. Since
thioacetazone was less expensive than PAS, trials
of isoniazid plus thioacetazone were carried out in
comparison with the standard regimen of isoniazid
plus PAS, for the duration of 12 months. A South
India study showed that thioacetazone was an
acceptable alternative, even if complicated by a
higher risk of side effects.10
Importantly, trial experience also showed that
direct observation and follow up played a pivotal
role in making domiciliary treatments effective.
The comparison the results obtained by routine
treatment services with those achieved in clinical
trials by the East Africa Tuberculosis Investigation
Centre and the British Medical Research Council in
Kenya indicated that, although the three drug
routine combination regimen with streptomycin,
isoniazid and thiacetazone was more powerful, the
two drug combination of isoniazid and thiacetazone
administered in ‘‘trial mode’’ gave patients a 10%
better bacteriological outcome at 12 months.11The 1970s: the introduction of rifampicin
and the 6-month short course
The discovery of rifamycins and of rifampicin,12 with
their introduction in the armamentarium of anti-
tuberculous drugs in 1966 13–15 prompted renewed
investigation on the reduction of treatment dura-
tion: eventually, the 6 months short-course che-
motherapy, with combinations of rifampicin,
isoniazid and pyrazinamide became standard.
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carried out in East Africa and Zambia in association
with the British Medical Research Council. In this
study, four 6-month daily regimens with streptomy-
cin, isoniazid and rifampicin (SHR); streptomycin,
isoniazid and pyrazinamide (SHZ); streptomycin,
isoniazid and thiacetazone (SHT) and streptomycin
plus isoniazid (SH) were compared with a standard
18-month streptomycin, isoniazide and thiacetazone
(STH for 2 months and then HT for 16 months)
regimen. The study demonstrated the efficacy of
the 6 months regimens and the superiority of the
rifampin or pyrazinamide containing regimens, as
the 6 month SHT and SH regimen had the highest
relapse rates at 30 month follow up (22–32%), with
the SHR regimen producing the lowest one (2%), that
was not significantly different from that obtained
with the 18 month standard treatment (3%).16
Fox and Mitchison, with the Medical Research
Council, developed a pharmacokinetic rationale
from clinical and laboratory studies, whereby
isoniazid and rifampin were considered as complete
bactericidal drugs, being capable of killing bacteria
in all environments, while streptomycin and pyrazi-
namide were ‘‘half’’ bactericidal drugs, being the
former active in the more alkaline extracellular
milieu and the latter active on the more acidic
intracellular environment. Interestingly, streptomy-
cin and pyrazinamide were perfectly complemen-
tary drug which, together, made a very powerful
bactericidal combination.17 Following this reason-
ing, the East African SHR short-course regimen
contained two and a half bactericidal drugs and
the almost equally powerful SHZ regimen contained
two full killers. In contrast, the SHT and SH less
powerful 6-month regimens contained only one and
a half killer. The East African trial so suggested that
at least two full bactericidal drugs were required to
successfully cut treatment duration from 12–18
months down to a 6-month short course.17
A number of randomized trials followed suit, in
East Africa, Madras, Hong Kong, Singapore and
Algeria. In a second East African study, the 6-month
SHR daily regimen, the best arm of the previous
study, was compared with a similar regimen without
streptomycin (HR daily for 6 months) and with two
regimens where rifampicin was given only during the
first 2 of the 6-month course, with the addition of
pyrazinamide (SHRZ daily for 2 months plus TH daily
for 4 months and SHRZ daily for 2 months plus SHZ
twice per week for 4 months) in order to explore the
efficacy of limiting rifampicin administration to the
first 2 months of treatment. Interestingly, the study
showed that 2SHRZ, the regimen with three full
bactericidal drugs, produced better bacteriological
results at 2 months, thereby suggesting that the useof such a combination in the initiation phase of
treatment could lead to complete elimination of all
susceptible organisms.18
After a subsequent East African study of 4-
month, short-course therapy using the same initia-
tion scheme (2SHRZ) followed by three different, 2-
month continuation schemes using either isoniazid,
isoniazid and rifampin, isoniazid and pyrazinamide
or the three drugs, was interrupted for an
unacceptably high number of relapses,19 a fifth
study was undertaken with which the role of
pyrazinamide in short-course therapy was to be
established. This study tested the same 2-month
initiation therapy (2SHRZ) followed by four differ-
ent continuation regimens of 4 months i.e., 4HR,
4HZ, 4H or 6H.20 The study showed that, after the
common initiation phase with 2SHRZ, the 4HR
continuation regimen was significantly better than
all others, with only 2% relapses at 24 months after
the completion of treatment. The 4HZ continuation
regimen, with 8% relapses, was no better than the
4H with 10%. This, together with the finding that
the 6H regimen resulted in only 3% relapses,
suggested that the contribution of pyrazinamide
was essential during the 2-month initiation phase of
the short-course combination regimens, but not
thereafter.
Similar results were obtained in a study of the
Research Committee of the British Thoracic Asso-
ciation that found that streptomycin or ethambu-
tol, with pyrazinamide added to isoniazid and
rifampicin during the 2-month initiation phase
(2SHRZ or 2EHRZ) follwed by 4 HR equalled the
standard 9HR with negligible relapse rates21 and by
the Algerian working group’s study which found
that a similar 6-month regimen had better results
than a 12-month standard treatment.22
The Singapore Tuberculosis Service/British Med-
ical Research Council study also confirmed the
efficacy of short-course regimens using streptomy-
cin, isoniazid, rifampicin and pyrazinamide in the
initiation phase with isoniazid plus rifampicin in the
continuation phase: In addition, it confirmed that a
4 months course was ineffective. In this study the
2SHRZ, 4HRZ short-course regimen produced no
relapses at 24 months after treatment cessation
and the 2SHRZ, 4HR regimen 2.5%, while with the
shorter regimens (2SHRZ, 2HRZ or 2HR) 8% and
11.8% relapses were observed, respectively.23The 1980s: intermittent short-course
regimens and DOTS
With the background that supervised, treatment
administration in trial mode had proven superior to
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rifampicin and pyrazinamide, pressed tuberculosis
services throughout the developing world to find a
short-course intermittent regimen that could be
given to outpatients under supervision. Two im-
portant studies were carried out at the Hong Kong
Chest Service with the collaboration of the British
Medical Research Council to determine the best
regimen for fully supervised outpatient treatment.
In the first study, a fully intermittent 6-month
regimen of streptomycin, isoniazid, rifampicin and
pyrazinamide three times weekly for 4 months
(4SHRZ3), followed by streptomycin, isoniazid and
pyrazinamide (2SHZ3), resulted in a bacteriological
relapse rate of 6% at 18 months in patients with fully
drug-sensitive bacteria, with an even higher relapse
rate with isoniazid-resistant strains.24 The second
study, evaluated four three-times weekly intermit-
tent short-course regimens containing isoniazid and
rifampicin together with (i) streptomycin, pyrazina-
mide, and ethambutol (6SHRZE3), (ii) streptomycin
and pyrazinamide (6SHRZ3), (iii) streptomycin and
ethambutol (6SHRE3), or (iv) pyrazinamide and
ethambutol (6HRZE3). As a control, a daily regimen
of isoniazid, rifampicin, pyrazinamide and etham-
butol (6HRZE) was used. At 24 months after the
completion of treatment, the bacteriological re-
lapse rate was 1% for the three-weekly regimens
with isoniazid and rifampicin plus streptomycin and
pyrazinamide and for the daily regimen vedrsus an
almost equally low 2% for the regimen with
pyrazinamide but no streptomycin. Strikingly, re-
lapse the rate of the regimen not containing
pyrazinamide was up to 8%.25 Very importantly, the
5-year follow up of the same study showed that
among patients with drug-susceptible pre-treatment
strains there were 3.4% relapses in the pyrazina-
mide-containing regimens, compared to 10.3% in the
non-pyrazinamide series. In addition, the pyrazina-
mide containing regimens were also very effective
on isoniazid and streptomycin resistant strains as
less than 4% relapses were observed.26
This study was important for it confirmed the
sterilizing role of pyrazinamide, in the association
with isoniazid and rifampicin, in the induction
phase of short-course chemotherapy. Further, it
determined that the role of streptomycin was
limited to the prevention of drug resistance, or
further drug resistance in isoniazid resistant
strains. Collectively, the data indicated that an
intermittent regimen based upon isoniazid and
rifampicin, with pyrazinamide and streptomycin
given for a shorter period would save costs and
increase manageability of domiciliary treatments
while reducing side effects at no bacteriological
cost.Another important study was carried out by the
Singapore Tuberculosis Service, also in collabora-
tion with the British Medical Research Council, with
which it was established the role of pyrazinamide
and streptomycin in short course, intermittent
regimens. This study examined three treatment
protocols with streptomycin, isoniazid, rifampicin,
and pyrazinamide for two months (2SHRZ), or for 1-
month (1SHRZ), or for 2 months without strepto-
mycin (2HRZ), followed by three-times-weekly
isoniazid and rifampicin (H3R3) up to 6 months for
all patients. The data showed that, in patients with
drug sensitive strains, relapse rates were less than
1% and that, importantly, they were only 3% in the
isoniazid and streptomycin resistant.27
A similar trial was carried out at the Tuberculosis
Research Centre in Madras, India. In this study,
three short-course chemotherapy regimens were
evaluated in patients with newly diagnosed, bac-
teriologically positive pulmonary tuberculosis: pa-
tients were allocatrd to either rifampicin,
streptomycin, isoniazid and pyrazinamide daily for
2 months, followed by streptomycin, isoniazid and
pyrazinamide twice weekly for a total of 5 (2SHRZ/
3SHZ2) or 7 months (2SHRZ/5SHZ2) or to the same 7
month regimen but without rifampicin (2SHZ/
5SHZ2). The result at 5 years indicated a slightly
higher percentage of bacteriological relapses,
compared to the Hong Kong and the Singapore
studies, with 7% for the 5-month rifampicin regi-
men, 4% for the 7-month rifampicin regimen and 7%
for the 7 month no-rifampicin regimen. In addition,
a 10% relapse rate was observed among isoniazid or
streptomycin resistant patients.28
Eventually, the 1980s studies brought to the
recommendations of the International Union
Against Tuberculosis and Lung Disease (IUATLD),
indicating isoniazid, rifampicin, pyrazinamide for
the 2-month induction phase followed by isoniazid
and rifampicin for the 4-month continuation phase
of the 6-month daily regimen. The same recom-
mendations also indicated adding ethambutol or
streptomycin in the initial phase of the three times
weekly regimen.29 Thus, with these trial-validated,
intermittent short-course chemotherapy regimens,
directly observed therapy (DOT) became feasible in
the tuberculosis services of high prevalence coun-
tries. With the DOT strategy was developed by the
IUATLD together with national tuberculosis pro-
grammes, the WHO recommended directly super-
vised treatment consisting of a 2-month daily
regimen of isoniazid, rifampicin, pyrazinamide,
ethambutol and streptomycin (2HRZE7 or 2SHRZE7)
followed by 4-month continuation with either daily
or intermittent isoniazid plus rifampicin (4HR7 or
4HR3), for patients with newly diagnosed smear
ARTICLE IN PRESS
Chemotherapy and diagnosis of tuberculosis 2089positive disease. As a second option, an entirely
intermittent 6-month treatment was recommended
(2HRZE3/4HR3).
30
An 8-month regimen with the same induction
phase (2HRZE7 or 2HRZE3) and isoniazid plus
thioacetazone in the continuation phase (6HT)
was recommended for use in countries with limited
financial resources. However, with the advent of
the Human Immunodeficiency Virus (HIV) epidemic,
being HIV-infected patients at increased risk of
severe, in some cases fatal, dermatological toxic
effects from thioacetazone, the WHO recommen-
dations were modified and in the 8-month regimen
above, ethambutol (6HE) was substituted for
thioacetazone in the 6-month daily isoniazid plus
thiacetazone continuation phase.30The new drugs and regimens of the 1990s
Are the intermittent regimens developed during
the past 30 years up to the task of curing 85% of
pulmonary tuberculosis patients, as per the goals of
the WHO tuberculosis programme?.31
In the late 1990s studies have been carried out on
intermittent regimens with newer rifamycin deri-
vatives. A Centres for Disease Control and the
Tuberculosis Trials Consortium trial compared once-
weekly rifapentine, in combination with high dose
isoniazid (15mg/kg) in the continuation phase of a
standard intermittent regimen, with twice-weekly
isoniazid and rifampicin. The study reported 2-year
crude rates of failure or relapse of 9.2% in the
rifapentine arm and of 5.6% in the control treat-
ment.32 A Hong Kong study compared 600mg
rifapentine plus 15mg/kg isoniazid, once-weekly
or every two of 3 weeks, with trice-weekly
isoniazid plus rifampicin in the continuation phase
of a standard trice weekly streptomycin, isoniazid,
rifampicin and pyrazinamide regimen (2SHRZ3).
This study found 5-year relapse/failure rates of
10.8% and 11.7%, respectively, for the rifapentine
arms compared to 4.2% for the standard HR3
regimen.33
A trial of rifabutin 300mg plus isoniazid twice-
weekly as the continuation phase of a standard
daily/intermittent regimen of isoniazid plus pyrazi-
namide and ethambutol, with rifabutin substituted
for rifampicin. The 2-year projection of the failure/
relapse rate was of 6.6%. Strikingly though, notwith-
standing the directly observed administration of all
drugs doses, eight of the nine relapses observed
were due to acquired rifampicin resistance.34
Concerns about the ultimate efficacy of inter-
mittent therapy regimens have been raised by a
Cochrane review35 and by a recent systematicreview that analyzed 20 rifampicin-containing
short-course chemotherapy regimens including 32
study groups of non-multi-drug resistant, non HIV
tuberculosis.36 These studies point to the increased
relapse rates observed with standard 6-month
intermittent regimens, where the total dose of
anti-tuberculous drugs appears to be related with
the bacteriological outcome. These observations
suggest that streamlined intermittent treatments
may pose the threat of increased rifampicin
resistance, hence of selecting multiple drug resis-
tant strains, unless careful pharmacokinetic eva-
luations of the new treatments are used in the
study design.37–39The changing epidemic: multi-drug resistant
tuberculosis (MDR-TB)
With the introduction of streptomycin, it rapidly
became apparent that the mycobacterium would
inevitably acquire drug resistance during the course
of chemotherapy and it was with the introduction
of PAS that it became understood that combination
drug treatment was mandatory to prevent, or
delay, the arising of drug resistant Mycobactarium
tuberculosis strains.2,3 In the late 1960s trials, 6%
of the patients enrolled had primary resistance to
at least one drug and only 0.4% had strains resistant
to all three drugs used i.e., streptomycin, isoniazid
and PAS.9
In the 1980s, streptomycin or isoniazid resistance
was seen in about 10% of clinical trial subjects and
in 5% resistance was to both drugs. However,
rifampicin-based, standard short-course regimens
obtained 90% or greater cure rates in streptomycin
and isoniazide resistant subjects.27 With wide-
spread use of rifampicin-containing regimens,
resistance to multiple drugs, notably against the
two major bactericidal drugs isoniazid and rifampi-
cin, appeared. In the US, 0.5% of new cases and
3.0% of recurrent cases were resistant to both
isoniazid and rifampicin in 1982 but this proportion
increased to 3.1% and 6.9% by 199140 and similar
figures have been reported worldwide.41 Hence,
the growth of MDR-TB prevalence has become the
major threat that the tuberculosis epidemic poses
today.
The genes coding for resistance to isoniazid are
katG, a gene involved the scavenging toxic per-
oxides produced by phagocytes that’s thought to be
required for protection against oxygen free radicals
within the macrophage and that’s required for the
generation of isoniazid toxic products,42 the inhA,
the oxyR, the kasA and ahpC genes. The rpoB gene
has been identified as the gene responsible for
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mycin, embB for ethambutol and pncA for pyrazi-
namide, inhA for ethionamide, rrs for kanamycin
and, finally, the gyrA and gyrB genes for fluoroqui-
nolones.43
Multi-drug resistance can be conferred by a
single mutational event the genes coding for
multi-drug efflux transporters, membrane proteins
that recognize dissimilar toxic compounds and
pump them out of eukaryotic and bacterial cells.
Although efflux pump genes have been identified in
mycobacteria, and M. tuberculosis, in particular,
they do not seem to play a major role in the
emergence of MDR strains.44–46 To the contrary,
multi-drug resistance is thought to be the conse-
quence of stepwise accumulation of random muta-
tions in the chromosome selected under the
environmental pressure of chemotherapy. These
finding have important implications for treatment
program strategy.47 In this regard, it was observed
that short-course chemotherapy regimens including
four or five drugs (rifampicin, isoniazid, pyrazina-
mide and ethambutol or streptomycin) were still
effective in the presence of resistance to isoniazid
alone and longer course protocols could still treat
patients with rifampicin mono-resistance,48,49 in
contrast, resistance to isoniazid and rifampicin
combined i.e., multi-drug resistance or MDR-TB
dramatically impacts upon treatment. With MDR-TB
the course of treatment needs prolongation from
the standard 6 months to 18–24 months and the
cure rate decreases from nearly 100% to less than,
or equal to, 60%.40
From the 1990s to the present day, a number of
reports have described the treatment of cases of
MDR-TB. In the retrospective study of Goble and
colleagues on the treatment of 171 MDR-TB
patients admitted to a specialized centre from
1973 to 1983, bacteriological conversion was
observed in 65% of cases and cure, defined as
bacteriological negativity for at least 3 months, in
56%. However, if the default rate of 21% is taken
into account, the ‘‘intention to treat’’ cure rate
would have been a mere 43%50. Higher ‘‘intention
to treat’’ cure rates were observed, almost 20
years later, in Yew’s et al. Hong Kong study of 106
patients carried out between 1990 and 2000 [78%
cure rate51], in the 31 cases of the inpatient arm of
the 1994–1997 USA study of Narita and coworkers
[79% cure rate 52], in the 75 cases of the 1996–1999
Peruvian domiciliary study of Mitnick and coworkers
[73% cure rate 53] and in the 204 cases of the
2000–2001 Latvian study of Lemaine and collea-
gues, who reported an ‘‘intention to treat’’ cure
rate of 66%.54 The Turkish study of Tahaoglu and
colleagues of 158 cases treated between 1992 and1999 also reported a higher ‘‘intention to treat’’
cure rate 77%.55 However, the interpretation of the
study results is hampered by having MDR-TB been
defined clinically i.e., by the lack of sputum
conversion after 5 months of standard treatment
instead of bacteriologically. The above recent
studies included, albeit in a non randomized
fashion, (i) more than five drugs, (ii) the fluroqui-
nolones cyprofloxacin, ofloxacin or levofloxacin in
most treatments and (iii) second line drugs such as
aminoglycosides, cycloserine and ethionamide.
Some other studies reported instead dimmer
outcomes and the, such as the French nationwide
observational 1994 study of Flament-Saillour and
colleagues, who reported an ‘‘intention to treat’’
cure rate of 33% among their 84 cases,56 the
1997–1999 Indian study of Subhash and coworkers
who reported an ‘‘intention to treat’’ cure rate of
32% in their 100 cases 57 and the 1998–2000 South
Korean study of 142 cases reported by Park and
colleagues whose ‘‘intention to treat’’ cure rate
was of 44%, due the very high default rate.58
The Stop TB Department of WHO estimates that
there were 458,000 (95% confidence limits,
321,000–689,000) incident MDR-TB cases (including
new and re-treatment cases) in 2003 worldwide.41
According to the WHO surveys, drug resistance was
strongly associated with previous treatment. In
previously treated patients, the probability of any
resistance was over 4-fold higher, and of MDR-TB over
10-fold higher, than for untreated patients. The
overall prevalence of drug resistance was often
related to the number of previously treated cases
in the country. Among countries with a high burden of
TB, previously treated cases ranged from 4.4% to
26.9% of all patients registered in DOTS programmes.
In the two largest high-TB burden countries (China
and India), re-treatment cases accounted for more
than 20% of sputum smear-positive cases.59 In detail,
in patients never previously treated, the median
prevalence of resistance to any of the first-line drugs,
most commonly streptomycin and/or isoniazid, was
10.7% (range 0–57.1%); although 20 survey sites
exceeded 20%. The median prevalence of MDR-TB
was 1.2% (range 0–14.2%); with 11 sites exceeding
the 6.5% threshold for extreme values. In patients
previously treated, the median prevalence of any
resistance was 23.3% (range 0–82.1%) and of MDR-TB,
7.7% (range 0–58.3%).60
A drug regimen to treat TB cases resistant to
isoniazid and rifampicin is currently 450 times
more costly than the cheapest short-course regi-
men for drug-susceptible cases, although nego-
tiated through the World Health Organization’s
Green Light Committee. Thus, it could cost more to
treat the new TB cases that are MDR than all other
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managing MDR TB cases that have previously failed
treatment, would demand in many countries a
significant fraction of the overall budget for TB
control.61 The same may happen in industrialized
countries, where drug resistant and MDR-TB are
often associated with social problems such as
homelessness, illegal immigration, drug abuse or
mental illness all rendering domiciliary care un-
feasible. Drug resistance dramatically increases the
cost of TB care as it requires, in addition to using
more expensive drugs, lengthy in-hospital isolation,
the major component of hospital costs.62The new epidemic of the 1990s: HIV
infection and tuberculosis
Since the first cases of HIV infection were recog-
nized 25 years ago, the AIDS epidemic has become
one of the major world’s health problems: an
estimated 39 million people live with HIV at the end
of 2005, world-wide, with four million newly
infected with HIV and three million loosing their
lives to AIDS.63 The HIV epidemic and tuberculosis
have fuelled each other in Africa, almost doubling
tuberculosis incidence from the 100–200 cases per
100,000 population incidence of the 1980s to the
200–400 per 100,000 of 2005.64
Since the beginnings of the epidemic, laboratory
and clinical studies characterized the HIV infection
for being dominated by progressive impairment of
antigen-specific T-cell mediated immune re-
sponses65 and by progressive susceptibility to
infections as well. Subsequent immunological stu-
dies, showing that mycobacteria have the ability to
activate HIV replication within the mononuclear
phagocytes and to accelerate the spread of viral
infection,66 established a link between the in-
creased susceptibility to tuberculosis, brought
about by HIV infection, and accelerated HIV
progression, caused by M. tuberculosis.
In this regard, clinical and epidemiological
studies have elucidated the role played by HIV
infection in tuberculosis morbidity and mortality.
The first series of tuberculosis cases in HIV-infected
persons were described in the early 1980s in the US
and Europe among population groups at higher risk
of tuberculosis reactivation, such as the immigrant
from high prevalence areas or intravenous drug
users67,68 and it was found that HIV co-infection
confers upon the carriers of latent M. tuberculosis
infection a greater than 100-fold risk of developing
active tuberculosis.69
The HIV epidemic had and will have a major
impact upon TB, and may be also a major factor forthe spread of MDR-TB. In the New York MDR-TB
epidemic of the 1990s it was found that, contrary
to observations in the HIV non-infected, HIV
infection was associated with a higher proportion
of primary drug resistance.70 It is thought that HIV-
infected persons may be more exposed to drug
resistant isolates for their very risk factors, such as
homelssness and drug abuse. In addition, HIV-
seropositive patients infected with resistant organ-
isms may rapidly progress to active disease, even
though resistant organisms might be less virulent
than susceptible organisms. Third, as HIV-infected
tuberculosis patients are less likely to be
cured,71,72 they may be at higher risk of developing
drug resistance, as the recent rifapentine trial has
indicated.73 As a result, a number of MDR-TB
outbreaks involving a majority of HIV-infected
patients have occurred in recent years in hospitals
and clinics, shelters and the community, a warning
that MDR-TB might become epidemic.70,74–76Diagnostics
Microbiology, from acid fast stains to DNA
amplification
The diagnosis of M. tuberculosis infection is more
difficult to establish than with almost every other
common bacterial infection. The specific micro-
biological stains and culture procedures still widely
used for M. tuberculosis date back to 1882 Robert
Koch’s announcement to the Berlin Physiological
Society that he observed and isolated the causative
organism of tuberculosis.77
Examination of sputum smears for acid-fast
bacilli (AFB) still is the most rapid way to obtain
evidence of tuberculous infection. However, not all
infected individuals have detectable M. tubercu-
losis in AFB-stained smears and acid fastness does
not distinguish M. tuberculosis from non-tubercu-
lous mycobacteria. Cultures in selective media are
more sensitive, but their outcome is delayed by the
extremely low growth rate of mycobacteria. Con-
trary to a number of environmental mycobacteria
that are rapid growers, yielding colonies in 7 days
or less, M. tuberculosis exhibits a slow growth rate,
requiring 14–21 days to generate visible colonies
and does not produce any pigment.
Mycobacteria are neither Gram-negative nor
positive but they are characterized by acid fast-
ness: that depends upon the composition and the
integrity of the mycobacterial cell wall i.e., killed
or fragmented mycobacteria may not be acid fast.
The most popular acid fast staining methods have
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and the Kinyoun techniques, or auramine O, a
fluorescent dye.78 Since fluorochrome-stained
slides may be viewed at lower magnification
(250–450 ) thus enabling the microscopist to
rapidly screen a high number of fields, fluorescent
staining is more sensitive than basic fuchsin
staining. The lower limit of detection of AFB
sputum smears has been estimated at 0.51 104
microorganisms per ml of sample, although higher
speed centrifugation has been shown to improve
recovery up to 90%,79,80 and this has been the lower
diagnostic detection limit for over a century.
The diagnostic gold standard for microbiological
confirmation of the diagnosis of tuberculosis is the
growth in selective culture media is.81 Culture is
significantly more sensitive and specific than acid
fast smears and systems have been developed, in
the 1980s such as the BACTEC and the biphasic
culture systems, that provided faster recovery than
the traditional cultures in solid media.82,83
However, the most important progress in tuber-
culosis diagnosis was brought about by the intro-
duction of nucleic acid amplification assays by 1985
by Saiki et al. using the polymerase chain reaction
(PCR). The PCR was the first nucleic acid amplifica-
tion procedure capable of generating in vitro of
millions of copies of a specific DNA segment84
allowing the rapid detection and quantification of
few DNA copies with very high sensitivity and
specificity, hence becoming the most important
research advance of the last decades for the
identification of infectious agents in biological
and environmental samples.
In 1989, the first attempt at the identification of
M. tuberculosis in clinical samples was reported by
Brisson-Noe¨l and coworkers, using a 65 kDa myco-
bacterial gene that allowed both the detection of
mycobacterial DNA and the differential diagnosis of
M. tuberculosis vs. non tuberculous mycobacter-
ia.85 A number of other genes, among them the
highly popular IS6110 repeated sequence,86 has
been used in clinical research laboratories, how-
ever susceptibility of amplification procedures to
both false positives and negatives hampered
clinical use of these tests87,88 until automated,
robust commercial tests became available.89–94
With these tests in the clinical setting using
standardized clinical indicators of TB pre-test
probability, nucleic acid amplification has finally
been shown to be amenable to provide clinically
relevant positive and negative predictive
powers.95,96 Ten years later, the clinical utility of
nucleic acid amplification tests has been certified
by the USA Centers for Diseases Control, that
recommended the use of nucleic acid amplificationtests on sputum samples for the diagnosis of
pulmonary tuberculosis. In particular, the use of
nucleic acid amplification using the GenProbe MTD
test and the Roche Amplicor were recommended
for the rapid identification of M. tuberculosis in
AFB-positive sputum smears, where the diagnosis of
non-tuberculus mycobacterial infection may be
suspected. Furthermore, the Amplicor test was
recommended for the determination of the pre-
sence of amplification inhibitors in the sputum
sample in the case of a negative amplification of an
AFB-positive sputum. In addition, the use of the
MTD test was recommended for the diagnosis of
tuberculosis in AFB- sputum samples, in the
presence of clinically suspected of tuberculosis.97Delayed type hypersensitivity testing: skin
and blood tests
The tuberculin skin test is one of the oldest
diagnostic tests, as it was developed by R. Koch
and subsequently described by von Pirquet in
1907.98 The test identifies subjects infected by M.
tuberculosis. The intensity of the skin reaction may
grossly discriminate between M. tuberculosis and
M. avium or other non tuberculous infections,99 but
the test is susceptible to inter-operator variability,
to variability due to administration modalities such
as the multi-puncture or the intradermal injection
and to false negativity due to a number of clinical
conditions causing immune compromise.100,101 Most
importantly, cross reactivity with M. bovis BCG
represents the major limitation in surveying BCG
vaccinated populations, as vaccination induced
immunity may last for over 15 years.102,103
In the last decade, genomic studies have identi-
fied M. tuberculosis genome regions that are absent
from the genome of M. bovis BCG and from that of
most non-tuberculous mycobacteria. The region of
differentiation (RD)-1, that’s shared only by M.
tuberculosis, M. szulgai, M. marinum and M.
kansasii, encompasses the ESAT-6 (early secretory
antigen target-6) and the CFP-10 (culture filtrate
protein-10) proteins that are target of the specific
immune response against M. tuberculosis.104,105
Using these proteins, T-cell based, highly sensitive
and specific diagnostic test were developed that
measured interferon (IFN)-g released by memory
and effector T-cells in the blood of M. tuberculosis
infected individuals. Of such tests, the QuantiFER-
ON (QTF-TB) has been developed by Cellestis Ltd.,
(Carnegie, Victoria, Australia) and the T-SPOT.TB
(TS.TB) by Oxford Immunotec (Abingdon, UK), in
addition to a number of home-brewed T-cell-based
tests.106
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ities varying between 85% and 95% i.e., far greater
than that of the tuberculin skin test, when subjects
with active tuberculosis are tested as refer-
ents.107–111 Importantly, both the QTF-TB and the
TS TB have been shown to be insensitive to BCG
vaccination, with a resulting specificity of
98–100%.112,113 With regard to the identification
of contacts of TB cases, in vitro blood tests show
remarkable concordance with the tuberculin skin
test.114 Even more importantly, they show a
stronger correlation with exposure level and dura-
tion than the tuberculin skin test.115,116 The new
tests do also perform better than the tuberculin
skin test in the identification of latent TB infection
in immuno-compromised patients. The more labor-
ious Elispot test, by using determined numbers of
blood mononuclear cells in the assay, is less
susceptible to false negative results in the lympho-
penic patients. Accordingly the test has shown
greater sensitivity than the tuberculin test in active
tuberculosis of HIV co-infected subjects, both
adults and children.117
The clinical utility of the new immunologic tests
for latent TB infection has been recently acknowl-
edged by the USA CDC118 which recommended the
QFT-TB test for use in all of the instances where the
tuberculin skin test was insofar recommended.82
Furthermore, the British National Institute for
Health and Clinical Excellence (NICE) recently
published a document that, based upon a cost
benefit analysis, recommends the use of in vitro
blood tests (i) to confirm an unreliable tuberculin
skin test, (ii) where the prevalence of false positive
skin reactions is expected to be high, e.g., in BCG
vaccinated populations and laboratory logistics
would allow the use of the new tests.119Serology: a 1940s promise not yet delivered
The antibody response to M. tuberculosis is
generally thought not to reflect anti-tuberculous
cell mediated immunity, although the rising of
antibody titers against selected antigens derived
from purified protein derivative (PPD) of tuberculin
seems to follows the appearance of skin reactivity
in BCG vaccinated subjects 120 and in M. tubercu-
losis exposed individuals,121 a type of response not
observed with highly purified antigens.122
Back in the 1940s Middlebrook and Dubos devel-
oped an agglutination test using tuberculin-sensi-
tized erythrocytes that was very sensitive but had
little specificity due to wide cross reactivity of the
crude antigens used.123 Thirty years later, with the
advent of newer immunological methods, a numberof assays have been designed using increasingly
well-characterized antigens: from mycobacterial
sonicates, PPD fractions, glycolipid fractions to
synthetic lipids and purified proteins. Antigen 5,
also known as the 38 kDa antigen has been
evaluated in an ELISA format with sensitivities
varying from 65% to 90% and specificities from 80%
to 100%.124 The A60 antigen, a thermostable
component of PPD cross reacting with Nocardia
and Corynebacterium species, has been used in IgG
and IgM assays with sensitivities varying from 60% to
over 90% and specificities from 80% to 100%.125,126
Antigen 90 has been used for the detection of
specific IgA in sera or body fluids with 70%
sensitivity and 90% specificity.127 Lipoarabinoman-
nan (LAM), a mycobacterial lipoglycan, has been
used in serological tests on HIV-negative and -
positive TB patients, showing sensitivities varying
from 21% to 89% in the HIV-negative, but only from
7% to 40% in the HIV-positive patients.128,129 In the
ideal application of serological tests i.e., the
diagnosis of extrapulmonary tuberculosis, sensitiv-
ities observed ranged from 60% to 98%.130
The latest development in tuberculosis serology
is represented by multi-antigen test using purified
antigens. It has been recently shown that an ELISA
test including the 38 kDa antigen, LAM, MPT-64 and
glutamine synthase could achieve 93% sensitivity
and 76% specificity when used combination of AFB
microscopy, thus suggesting that in the appropiate
epidemiological and laboratory context this test
could be use to improve the performances of the
AFB smear exam alone.131
Serological tests do not seem to of help with the
diagnosis of sputum-positive pulmonary tuberculo-
sis. However, used in conjunction with AFB smears,
they may have a role in patients unable to provide
an adequate sputum sample. They may also be of
use in individuals suspected of bearing extra-
pulmonary tuberculosis.132Back to the future
Er Griegg proposed some years ago a historically
enticing epidemiologal hypotesis where M. tuber-
cuolosis epidemic wave spreads into naı¨ve popula-
tions limited by the death of the susceptible and
the emergence of immune resistance in the
population, until it subsidizes in the span of 2–3
centuries. The current epidemic, originated at the
dawn of the industrial revolution in the 17th
century’s England, reached its peak there at the
end of the 18th century to make its way into
continental Europe and Northern America during
the first half of the 19th century, then into Eastern
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annual death rate of 1% of the population at the
peak of the wave, to slowly decline therafter.133
A century of medical discoveries, with Brehe-
mer’s pioneering sanatoria in the mid 1800s, Koch’s
isolation of M. tuberculosis in 1882,77 Forlanini’s
invention of pneumothorax in 1884,134 Schatz and
Waksman’s discovery of streptomycin in 1944,135
has been accompanied by a steady decline in TB
morbidity and mortality in Western Europe and the
USA. The past 50 years of tuberculosis research has
brought rapid diagnosis to identify all new cases
and powerful chemotherapy to cure it. Now M.
tuberculosis could be eradicated, economical,
social and political conditions permitting.References
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